AZ, Roche to ‘bottle medchem’ for pharmasphere
This article was originally published in Scrip
Three hundred and fifty-thousand rules is a lot of rules, even for a large pharmaceutical company. But two of the biggest firms – AstraZeneca and Hoffmann-La Roche - have just signed a collaboration that promises to generate many times more than that. The rules are part of an evolving engine that might tame the frustratingly empirical art of medicinal chemistry, and allow ‘bottled’ medchem wisdom to be shared across the pharma and biotech sectors. Perhaps surprisingly, Pascal Soriot, the obvious human link between the two companies had nothing to do with pulling the deal together.
You may also be interested in...
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.
What does a good drug launch look like? Is pharma getting better at them? Which drugs are likely still to be in the top 20 in five years' time? Get the picture with Scrip's interactive infographic.